Merck & Co., Inc. (MRK) — closed signal from February 14, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 15, 2026.
Predicted vs. what happened
What happened
Reached 31% of the predicted growth at its peak, without hitting the target.
The thesis — published February 14, 2026
Merck is a steadier choice for the next few months. A new approval for KEYTRUDA, including an easier-to-give form, means the drug can be used for another type of ovarian cancer, which people see as good news. Headlines can push the price up quickly, but those moves can fade, so it's safer to wait for a drop before buying. The main worry is renewed debate about big drug company valuations.
Primary drivers
- KEYTRUDA approval lets it treat more ovarian cancer patients
- Seen as a steadier stock when markets are shaky
- Clear sales visibility from a strong drug franchise helps sentiment
- Buying after a pullback reduces the chance of chasing a short-lived spike
How it played out
MRK: target not reached inside the window
Lyra published MRK at $121.41 on 2026-02-14 with expected growth of 10%. The thesis pointed to a KEYTRUDA approval for more ovarian cancer patients, a steadier stock profile when markets were shaky, clear sales visibility from a strong drug franchise, and waiting for a pullback instead of chasing a short-lived spike.
Inside the window, MRK peaked at $125.14 on 2026-02-25, up 3.1%. It stayed below the $133.55 target and never reached it. By 2026-05-15, it ended at $111.38. The thesis only partially played out: the stock rose early, but the move fell short and then faded.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.